Skip to main content

ESOU20

Novosanis will be attending the 17th Meeting of the EAU Section of Oncological Urology in Dublin from 17 to 19 January 2020. Henk Joos, our Business Development Manager for Europe, is excited to meet you and provide insights in our solutions for (home-based) urine sampling for detection of infectious diseases and early-stage cancers.

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.